Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 2/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285603 | 0.96 | KDM5A (0.38) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL29286841 | 0.94 | ALDH1A1 (0.48) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL10988578 | 0.94 | ALDH1A1 (0.48) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL11725018 | 0.92 | ALDH1A1 (0.39) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL11789461 | 0.89 | TSHR (0.50) | ALDH1A1TSHRKDM5APHF8KDM4C | |
| SCHEMBL11519612 | 0.89 | TSHR (0.50) | ALDH1A1TSHRKDM5APHF8KDM4C | |
| SCHEMBL11523544 | 0.89 | TSHR (0.50) | ALDH1A1TSHRKDM5APHF8KDM4C | |
| SCHEMBL29286822 | 0.86 | ALDH1A1 (0.48) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL23940294 | 0.85 | TSHR (0.59) | ALDH1A1TSHRKDM5APHF8KDM4C | |
| SCHEMBL2518642 | 0.85 | TSHR (0.59) | ALDH1A1TSHRKDM5APHF8KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4655402-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | Providence Therapeutics Holdings Inc. (CA) | 2025-12-03 | — | — | EP | disclosed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| EP-3394030-B2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-06-03 | — | — | US | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-22 | — | — | US | disclosed |
| EP-3394030-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | LMNA 1403/4885ALDH1A1 4687/4885TSHR 3222/4885 |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | LMNA 755/4885ALDH1A1 4876/4885TSHR 2825/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | LMNA 161/4885ALDH1A1 3260/4885TSHR 3848/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | LMNA 4390/4885ALDH1A1 3146/4885TSHR 2325/4885 |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | LMNA 1403/4885ALDH1A1 4687/4885TSHR 3222/4885 |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | LMNA 1403/4885ALDH1A1 4687/4885TSHR 3222/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | LMNA 458/4885ALDH1A1 4885/4885TSHR 1278/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | LMNA 1178/4885ALDH1A1 4882/4885TSHR 2474/4885 |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | LMNA 1403/4885ALDH1A1 4687/4885TSHR 3222/4885 |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | LMNA 1403/4885ALDH1A1 4687/4885TSHR 3222/4885 |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | LMNA 1403/4885ALDH1A1 4687/4885TSHR 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.